Work

GLP-1 Receptor Agonists and The Gut: Interactions Between Appetite, Diet and The Gut Microbiome

Year: 2026
Type: article
Abstract: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in the management of type 2 diabetes and obesity because they improve glycaemic control, reduce appetite and promote clinically meaningful weight loss. Their effects, however, extend beyond pancreatic glucose regulation. GLP-1 signalling participates in a gut–brain–metabolic network involving gastric emptying, satiety, food choice, intestinal physiology and microbial metabolites. Emerging research also suggests a bidirectional relationship between GLP-1 biology and the gut microbiome. Short-chain fatty acids and bile-acid derivatives generated by intestinal microorganisms may influence endogenous GLP-1 secretion, while GLP-1 RA treatment may alter the intestinal environment directly or indirectly through reduced food intake, dietary change, weight loss and gastrointestinal effects. Preclinical studies frequently report shifts in taxa such as Akkermansia and Lactobacillus, but human findings are heterogeneous and remain largely associative. Diet is a major confounder because GLP-1 RA therapy can change meal size, macronutrient intake and food preferences, all of which can independently modify the microbiome. This narrative review examines the interactions among GLP-1 receptor agonists, appetite regulation, dietary intake and the gut microbiome, with emphasis on mechanisms, human evidence, clinical nutrition implications and research gaps. Current evidence supports a biologically plausible gut–microbiome–GLP-1 axis, but does not yet justify microbiome testing or microbiome-directed supplementation as routine methods for predicting or enhancing GLP-1 RA response.
Language: English
Open Access status: diamond
OpenAlex ID: W7218165683
FWCI:
Cites: 11
Cited by:
Related to: 10